Literature DB >> 11521229

Mast cell involvement in fibrodysplasia ossificans progressiva.

F H Gannon1, D Glaser, R Caron, L D Thompson, E M Shore, F S Kaplan.   

Abstract

Fibrodysplasia ossificans progressiva (FOP) is a catastrophic genetic disorder of progressive heterotopic ossification associated with dysregulated production of bone morphogenetic protein 4 (BMP4), a potent osteogenic morphogen. Postnatal heterotopic ossification in FOP is often heralded by hectic episodes of severe post-traumatic connective tissue swelling and intramuscular edema, followed by an intense and highly angiogenic fibroproliferative mass. The abrupt appearance, intense size, and rapid intrafascial spread of the edematous preosseous fibroproliferative lesions implicate a dysregulated wound response mechanism and suggest that cells and mediators involved in inflammation and tissue repair may be conscripted in the growth and progression of FOP lesions. The central and coordinate role of inflammatory mast cells and their mediators in tissue edema, wound repair, fibrogenesis, angiogenesis, and tumor invasion prompted us to investigate the potential involvement of mast cells in the pathology of FOP lesions. We show that inflammatory mast cells are present at every stage of the development of FOP lesions and are most pronounced at the highly vascular fibroproliferative stage. Mast cell density at the periphery of FOP lesional tissue is 40- to 150-fold greater than in normal control skeletal muscle or in uninvolved skeletal muscle from FOP patients and 10- to 40-fold greater than in any other inflammatory myopathy examined. These findings document mobilization and activation of inflammatory mast cells in the pathology of FOP lesions and provide a novel and previously unrecognized target for pharmacologic intervention in this extremely disabling disease.

Entities:  

Mesh:

Year:  2001        PMID: 11521229     DOI: 10.1053/hupa.2001.26464

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  39 in total

1.  Sensory nerve induced inflammation contributes to heterotopic ossification.

Authors:  Elizabeth Salisbury; Eric Rodenberg; Corinne Sonnet; John Hipp; Francis H Gannon; Tegy J Vadakkan; Mary E Dickinson; Elizabeth A Olmsted-Davis; Alan R Davis
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

Review 2.  The immunological contribution to heterotopic ossification disorders.

Authors:  Michael R Convente; Haitao Wang; Robert J Pignolo; Frederick S Kaplan; Eileen M Shore
Journal:  Curr Osteoporos Rep       Date:  2015-04       Impact factor: 5.096

Review 3.  Retinoid roles and action in skeletal development and growth provide the rationale for an ongoing heterotopic ossification prevention trial.

Authors:  Maurizio Pacifici
Journal:  Bone       Date:  2017-08-19       Impact factor: 4.398

4.  Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.

Authors:  Harry J Han; Payal Jain; Adam C Resnick
Journal:  Bone       Date:  2017-08-02       Impact factor: 4.398

5.  Substance P signaling mediates BMP-dependent heterotopic ossification.

Authors:  Lixin Kan; Vitali Y Lounev; Robert J Pignolo; Lishu Duan; Yijie Liu; Stuart R Stock; Tammy L McGuire; Bao Lu; Norma P Gerard; Eileen M Shore; Frederick S Kaplan; John A Kessler
Journal:  J Cell Biochem       Date:  2011-10       Impact factor: 4.429

6.  An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.

Authors:  Salin A Chakkalakal; Deyu Zhang; Andria L Culbert; Michael R Convente; Robert J Caron; Alexander C Wright; Andrew D A Maidment; Frederick S Kaplan; Eileen M Shore
Journal:  J Bone Miner Res       Date:  2012-08       Impact factor: 6.741

7.  Opioid signaling in mast cells regulates injury responses associated with heterotopic ossification.

Authors:  Lixin Kan; Amelia A Mutso; Tammy L McGuire; Apkar Vania Apkarian; John A Kessler
Journal:  Inflamm Res       Date:  2013-12-11       Impact factor: 4.575

8.  Is there a biological basis for treatment of fibrodysplasia ossificans progressiva with rosiglitazone? Potential benefits and undesired effects.

Authors:  Renata Bocciardi; Roberto Ravazzolo
Journal:  PPAR Res       Date:  2010-06-16       Impact factor: 4.964

9.  Histologic identification of brown adipose and peripheral nerve involvement in human atherosclerotic vessels.

Authors:  Elizabeth Salisbury; John Hipp; Elizabeth A Olmsted-Davis; Alan R Davis; Michael H Heggeness; Francis H Gannon
Journal:  Hum Pathol       Date:  2012-06-27       Impact factor: 3.466

Review 10.  Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.

Authors:  Maurizio Pacifici; Eileen M Shore
Journal:  Cytokine Growth Factor Rev       Date:  2015-12-28       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.